1346674-11-0

Basic information

• Product Name: tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate
• Synonyms: tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate
• CAS NO: 1346674-11-0
• Molecular Weight: 238.29
• Mol File: 1346674-11-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate(1346674-11-0)
• EPA Substance Registry System: tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate(1346674-11-0)

Safety Data

• Hazardous Substances Data: 1346674-11-0(Hazardous Substances Data)

Upstream product

• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 
• 887594-13-0 tert-butyl 3-(2-cyanoacetyl)azetidine-1-carboxylate 
• 610791-05-4 azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 

Relevant articles and documents

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)

Recent data suggest that inhibition of dual leucine zipper kinase (DLK, MAP3K12) has therapeutic potential for treatment of a number of indications ranging from acute neuronal injury to chronic neurodegenerative disease. Thus, high demand exists for selective small molecule DLK inhibitors with favorable drug-like properties and good CNS penetration. Herein we describe a shape-based scaffold hopping approach to convert pyrimidine 1 to a pyrazole core with improved physicochemical properties. We also present the first crystal structures of DLK. By utilizing a combination of property and structure-based design, we identified inhibitor 11, a potent, selective, and brain-penetrant inhibitor of DLK with activity in an in vivo nerve injury model.

PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.